AR112333A1 - Pirrolopirimidina y derivados de pirrolopirimidina - Google Patents

Pirrolopirimidina y derivados de pirrolopirimidina

Info

Publication number
AR112333A1
AR112333A1 ARP180101945A AR112333A1 AR 112333 A1 AR112333 A1 AR 112333A1 AR P180101945 A ARP180101945 A AR P180101945A AR 112333 A1 AR112333 A1 AR 112333A1
Authority
AR
Argentina
Prior art keywords
pyrrolopyrimidine
derivatives
solvate
pharmaceutically acceptable
acceptable salt
Prior art date
Application number
Other languages
English (en)
Original Assignee
Galapagos Nv
Calchan Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galapagos Nv, Calchan Ltd filed Critical Galapagos Nv
Publication of AR112333A1 publication Critical patent/AR112333A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Saccharide Compounds (AREA)

Abstract

Reivindicación 1: Un compuesto de acuerdo con la fórmula (1), donde R¹ es H, CH₃, F o Cl; X es N, CH o C-CN; y R² es CH₃ o halógeno; o una sal farmacéuticamente aceptable, o un solvato, o una sal farmacéuticamente aceptable de un solvato de este; o un metabolito biológicamente activo de este.
ARP180101945 2017-07-12 2018-07-12 Pirrolopirimidina y derivados de pirrolopirimidina AR112333A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1711234.3A GB201711234D0 (en) 2017-07-12 2017-07-12 Pyrrolopyrimidine and pyrrolopyridine derivatives

Publications (1)

Publication Number Publication Date
AR112333A1 true AR112333A1 (es) 2019-10-16

Family

ID=59676761

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP180101945 AR112333A1 (es) 2017-07-12 2018-07-12 Pirrolopirimidina y derivados de pirrolopirimidina

Country Status (18)

Country Link
US (2) US11136325B2 (es)
EP (1) EP3652173A1 (es)
JP (1) JP7198263B2 (es)
KR (1) KR20200028436A (es)
CN (1) CN111094283A (es)
AR (1) AR112333A1 (es)
AU (1) AU2018300218B2 (es)
BR (1) BR112020000578A2 (es)
CA (1) CA3069358A1 (es)
CO (1) CO2020001346A2 (es)
GB (1) GB201711234D0 (es)
IL (1) IL271910B2 (es)
MX (1) MX2020000005A (es)
PH (1) PH12019502823A1 (es)
SG (1) SG11202000168UA (es)
TW (1) TWI794253B (es)
UY (1) UY37809A (es)
WO (1) WO2019012284A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201711234D0 (en) * 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives
CN111303155A (zh) * 2020-03-13 2020-06-19 深圳大学 靶向pak1抑制剂及其在抗肿瘤治疗药物中的应用
CN111704617B (zh) * 2020-06-15 2022-08-23 嘉兴特科罗生物科技有限公司 一种小分子化合物
KR102635126B1 (ko) * 2021-05-27 2024-02-13 한국과학기술연구원 엑토뉴클레오티드 피로포스파타아제-포스포디에스터라아제의 저해 활성을 갖는 신규한 피롤로피리미딘 유도체 및 이들의 용도
CN118338902A (zh) * 2021-07-28 2024-07-12 埃皮里姆生物股份有限公司 吡咯并[2,3-b]吡啶PGDH抑制剂及制备和使用方法
WO2023014049A1 (ko) * 2021-08-02 2023-02-09 한국화학연구원 신규한 피롤로 피리미딘 유도체 화합물, 이의 제조방법, 및 이를 유효성분으로 포함하는 대사성 간질환의 예방 또는 치료용 약학적 조성물
CN117865965B (zh) * 2024-01-08 2024-06-28 贵州省天然产物研究中心 吡咯并嘧啶-4-胺和吡唑并嘧啶-4-胺衍生物及制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1246623E (pt) 1999-12-02 2006-12-29 Osi Pharm Inc Compostos específicos para o receptor de adenosina a1,a2a e a3 e as suas utilizações
TW200306191A (en) * 2002-02-22 2003-11-16 Teijin Ltd Pyrrolopyrimidine derivatives
WO2004048565A1 (ja) 2002-11-22 2004-06-10 Takeda Pharmaceutical Company Limited アポトーシス関連蛋白質およびその用途
EP2058309A4 (en) 2006-08-04 2010-12-22 Takeda Pharmaceutical CONDENSED HETEROCYCLIC COMPOUND
JP2010513458A (ja) 2006-12-19 2010-04-30 ファイザー・プロダクツ・インク H−pgdsの阻害剤としてのニコチンアミド誘導体、およびプロスタグランジンd2の仲介による疾患を治療するためのその使用
CA2691448A1 (en) 2007-08-31 2009-03-05 Dominique Swinnen Triazolopyridine compounds and their use as ask inhibitors
WO2009123986A1 (en) 2008-03-31 2009-10-08 Takeda Pharmaceutical Company Limited Apoptosis signal-regulating kinase 1 inhibitors
TWI625121B (zh) 2009-07-13 2018-06-01 基利科學股份有限公司 調節細胞凋亡信號之激酶的抑制劑
WO2012080735A1 (en) * 2010-12-16 2012-06-21 Convergence Pharmaceuticals Limited Ask1 inhibiting pyrrolopyrimidine derivatives
GB201711234D0 (en) * 2017-07-12 2017-08-23 Galapagos Nv Pyrrolopyrimidine and pyrrolopyridine derivatives

Also Published As

Publication number Publication date
KR20200028436A (ko) 2020-03-16
RU2020106289A (ru) 2021-08-12
GB201711234D0 (en) 2017-08-23
AU2018300218B2 (en) 2021-12-16
TW201908312A (zh) 2019-03-01
CO2020001346A2 (es) 2020-05-29
UY37809A (es) 2019-02-28
CA3069358A1 (en) 2019-01-17
US20220169653A1 (en) 2022-06-02
JP2020530833A (ja) 2020-10-29
MX2020000005A (es) 2020-08-06
US11136325B2 (en) 2021-10-05
SG11202000168UA (en) 2020-02-27
JP7198263B2 (ja) 2022-12-28
RU2020106289A3 (es) 2021-11-10
BR112020000578A2 (pt) 2020-07-14
IL271910B2 (en) 2023-07-01
TWI794253B (zh) 2023-03-01
PH12019502823A1 (en) 2020-10-26
IL271910A (en) 2020-02-27
AU2018300218A1 (en) 2020-02-27
WO2019012284A1 (en) 2019-01-17
EP3652173A1 (en) 2020-05-20
US20200165259A1 (en) 2020-05-28
IL271910B1 (en) 2023-03-01
CN111094283A (zh) 2020-05-01

Similar Documents

Publication Publication Date Title
AR112333A1 (es) Pirrolopirimidina y derivados de pirrolopirimidina
AR116604A1 (es) Inhibidores de kras g12c
PE20221339A1 (es) Inhibidores de parp1
AR109349A1 (es) Compuestos y usos
ZA202006378B (en) N-heterocyclic five-membered ring-containing capsid protein assembly inhibitor, pharmaceutical composition thereof, and use thereof
EA202092263A1 (ru) Аминопиридиновые производные в качестве ингибиторов ctps1
AR115949A1 (es) Compuestos heterocíclicos
AR111315A1 (es) Derivados de indolina sustituidos como inhibidores de la replicación vírica de dengue
AR106141A1 (es) Métodos e intermediarios para la preparación de derivados de ácidos biliares
EA202191104A1 (ru) Производные аминопиридина/пиразина в качестве ингибиторов ctps1
AR103170A1 (es) Compuestos y composiciones farmacéuticas de los mismos para el tratamiento de desordenes inflamatorios y osteoartritis
AR117189A1 (es) Derivados de 6,7-dihidro-4h-pirazolo[1,5-a]pirazin indol-2-carboxamidas activos contra el virus de la hepatitis b (vhb)
AR103412A1 (es) Derivados de indol mono o disustituido como inhibidores de la replicación del virus del dengue
EA201692266A1 (ru) Ингибиторы фосфатидилинозитол-3-киназы
CY1125004T1 (el) Ετεροαρυλο υποκατεστημενες βητα-υδροξυαιθυλαμινες για χρηση στη θεραπεια της υπεργλυκαιμιας
EA201690911A1 (ru) Соединения диметилбензойной кислоты
AR111806A1 (es) Derivados de indol n-sustituidos
AR117920A1 (es) Inhibidores de la replicación del virus de la inmunodeficiencia humana
EA201791667A1 (ru) Соединения бензоксаборола и их применение
AR116947A1 (es) Derivados de urea 6,7-dihidro-4h-pirazolo[1,5-a]pirazinas-indol-2-carboxamidas activas contra el virus de la hepatitis b (vhb)
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CY1125355T1 (el) Πεντακυκλικη ενωση
NI201800063A (es) Compuesto de 1,3,4-tiadiazol y su uso en el tratamiento del cáncer
AR101696A1 (es) Compuestos de azetidiniloxifenilpirrolidina
EA202092159A1 (ru) Содержащий n-гетероциклическое пятичленное кольцо ингибитор сборки капсидного белка, его фармацевтическая композиция и их применение